Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alnylam
Biotech
Corsera launches with $50M for predictive AI tool, RNAi asset
Clive Meanwell and John Maraganore have launched a new biotech with a once-annual preventive heart disease candidate and a predictive AI tool.
Gabrielle Masson
Sep 2, 2025 6:30am
Regeneron posts phase 3 win, advancing push to muscle in on gMG
Aug 26, 2025 9:41am
BridgeBio touts extension study data for ATTR-CM drug acoramidis
Nov 18, 2024 3:38pm
Intellia, Alnylam post data on contrasting cardiomyopathy ideas
Nov 18, 2024 7:40am
Alnylam abandons clinical-stage Type 2 diabetes asset
Oct 31, 2024 10:27am
BridgeBio touts case for acoramidis with post hoc study analysis
Sep 30, 2024 9:37am
